Monopar Therapeutics Inc. (MNPR), a clinical-stage biopharmaceutical company, Thursday, announced that it has dosed the first patient in a phase Ia study evaluating therapeutic radiopharmaceutical MNPR-101-Lu in patients with solid tumor cancers.
MNPR-101-Lu combines MNPR-101, Monopar's antibody that selectively targets the urokinase plasminogen activator receptor, with the therapeutic radioisotope lutetium-177.
Urokinase plasminogen activator receptor is a protein that plays a role in tumor growth and spread and is found in many cancers, such as pancreatic, ovarian, triple-negative breast, and colorectal cancers.
The first patient dosed with MNPR-101-Lu has metastatic pancreatic cancer. Imaging using MNPR-101-Zr revealed the presence of uPAR expression in the patient.
MNPR-101-Zr for imaging is also under phase I trial and enrollment is underway.
MNPR closed Thursday's trading at $21.00, down 14.84%. In after-hours trading, the stock was up over 13% at $23.80.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.